Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Report highlights progress toward environmental, social and governance objectives

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company's commitment to society and stakeholders providing detailed insight into the company's CSR progress and environmental, social and governance (ESG) efforts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601006295/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

"Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Reducing our impact on the environment, fostering an inclusive culture and being active members of our communities gives our more than 100,000 colleagues the opportunity to make a difference every day."

Highlights from the company's annual CSR report include:

Environment

  • Achieved 12% reduction in absolute Scope 1 and 2 emissions compared to 2018, putting the company ahead of schedule towards its 2030 target to reduce Scope 1 and 2 greenhouse gas emissions by 30%, even as it expanded global capacity in 2020 and 2021.
  • Committed to net-zero emissions across its value chain by 2050, aligning the company's climate strategy and goals with the Paris Agreement, and expanding on its existing 2030 target.

Operations

  • Increased direct and indirect spending with small and traditionally underrepresented businesses from $1.3 billion to $2.0 billion. This is part of a Supplier Diversity Program designed to proactively promote more inclusive procurement practices that reflect the company's customer base, employees and communities.
  • Continued mobilization of company resources to accelerate development, manufacturing and distribution of products critical to the global pandemic response, becoming one of the largest testing suppliers to global relief organizations for use in more than 100 low- and middle-income countries.

Communities

  • Reached more than 100,000 students and 6,600 educators through science, technology, engineering and math (STEM) programming across 21 countries.
  • Volunteered more than 105,000 hours worldwide through local Community Action Councils.

Colleagues

  • Advanced its diversity and inclusion strategy including demonstrated progress in improving representation within company leadership positions.

In reporting our CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks including the Global Reporting Initiative (GRI) Sustainability Reporting Standards, United Nations Sustainable Development Goals (SDGs), the Value Reporting Foundation's SASB Standards and the Task Force on Climate-related Financial Disclosures (TCFD). The company makes additional topic-specific ESG data available through CDP, EcoVadis, and the voluntary disclosure of its annual EEO-1 information.

Learn more at www.thermofisher.com/csr

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×